Recombinant Human Flt3L Protein，His

Flt3L, or Fms-like tyrosine kinase 3 ligand, is a pivotal hematopoietic growth factor that plays a crucial role in the proliferation, differentiation, and survival of hematopoietic progenitor cells and dendritic cells. It is primarily involved in the regulation of immune responses and has garnered significant interest in cancer immunotherapy due to its ability to enhance the function of dendritic cells, which are vital for initiating T-cell-mediated immune responses. The recombinant form of Flt3L (recombinant Flt3L) has been developed for therapeutic applications, particularly in boosting the immune system's response against tumors. Studies have shown that administering recombinant Flt3L can promote the expansion of dendritic cells and other immune cell types, thereby potentially improving the efficacy of various cancer treatments. Additionally, Flt3L has been explored for its ability to enhance the engraftment of hematopoietic stem cells in transplantation settings, making it relevant in both cancer and regenerative medicine research. Given its critical role in immune system modulation, recombinant Flt3L is being investigated not only for its standalone effects but also in combination with other immunotherapeutic agents to overcome immune checkpoints and improve patient outcomes in oncological treatments. Overall, the research surrounding Flt3L and its recombinant protein form is a rapidly evolving field, with promising implications for enhancing immune responses in cancer therapy and cellular therapies.